Table 4.

Univariate analysis for identifying the risk factor for disease free survival and overall survival

	Disease-free survival		Overall survival
	HR(95%CI)	P value1	HR (95%CI)	P value1
Male	> 1.00 (0.54-1.87)	< 1.00	1.34 (0.75-2.41)	0.33
Age < 60	1.20 (0.61-2.36)	0.59	0.86 (0.46-1.61)	0.63
Bismuth type
IIIA	1.00		1.00
IIIB	1.95 (0.70-5.42)	0.20	1.07 (0.31-3.63)	0.92
IV	> 1.00 (0.52-1.95)	0.99	0.84 (0.47-1.51)	0.56
Pre-op AJCC 7th stage
IIIA	1.00		1.00
IIIB	0.86 (0.44-1.66)	0.64	0.88 (0.46-1.68)	0.70
IVA	0.55 (0.13-2.37)	0.42	0.70 (0.21-2.34)	0.57
IVB	2.51 (0.56-11.19)	0.23	2.43 (0.71-8.25)	0.16
Serum total bilirubin	0.76 (0.95-1.04)	0.76	1.01 (0.97-1.06)	0.66
Serum total bilirubin ≥ 3	1.21 (0.64-2.28)	0.56	1.40 (0.77-2.53)	0.27
Serum CA19-9	1.01 (> 1.00-1.01)	< 0.01	> 1.00 (1.00-1.01)	0.13
Serum CA19-9 ≥ 300	3.28 (1.68-6.41)	< 0.01	2.58 (1.39-4.78)	< 0.01
Variation of CA19-9 after NACCRT	1.07 (0.98-1.15)	0.12	1.02 (0.95-1.10)	0.61
Received NACCRT	1.05 (0.51-2.15)	0.91	0.65 (0.30-1.39)	0.27
Performed R0 resection	1.01 (0.50-2.04)	0.98	0.61 (0.33-1.15)	0.12
Tumor differentiation
Well	1.00		1.00
Moderately	2.30 (0.95-5.55)	0.06	1.34 (0.63-2.83)	0.45
Poorly	1.25 (0.15-10.47)	0.84	3.66 (1.08-12.33)	0.04
Indeterminate	3.30 (0.92-11.88)	0.07	1.21 (0.37-3.97)	0.75
Microvascular invasion	1.37 (0.73-2.56)	0.33	1.89 (1.02-3.51)	0.04
Perineural invasion	0.58 (0.22-1.49)	0.25	1.35 (0.53-3.45)	0.53
Lymph node metastasis	1.01 (0.54-1.86)	0.98	> 1.00 (0.56-1.78)	0.99
Received adjuvant treatment	0.78 (0.42-1.45)	0.43	0.77 (0.43-1.36)	0.36

¹P values were determined with a univariate Cox proportional hazards regression test. AJCC: American Joint Committee on Cancer; CA19-9: Carbohydrate antigen 19-9; NACCRT: Neoadjuvant concurrent chemoradiotherapy.